BOSTON–(BUSINESS WIRE)–Elucid Bioimaging Inc. (“Elucid”) today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology and intellectual property behind its products. Elucid is aware of a lawsuit filed by Heartflow, Inc., on October 22, 2026. Elucid will respond to and defend against the claims in the lawsuit through the appropriate legal channels. “Elucid was founded to help phy
See full post here as originally published on this site
